# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Steven Lichtman maintains MannKind (NASDAQ:MNKD) with a Outperform and raises the price target from $10 ...
MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products...
Rodman & Renshaw analyst Brandon Folkes initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Pri...
Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $6.5 price target.